I wouldn't go that far. Single product, dependant on a foreign partner. What if DRL run into similar issues to Ranbaxy? Sure ACL isn't as speculative as it once was, but its still specco.
Having said that, I think we in for some seriously good wealth creation, but I don't have a dollar in here that I can't burn.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable